[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, ofatumumab has been shown to be effective for the treatment of multiple sclerosis. Document [0] states that ofatumumab is approved in several countries worldwide for the treatment of relapsing forms of multiple sclerosis and has been found to be more effective than oral teriflunomide in reducing relapse rates and limiting disability progression. Document [1] also confirms that ofatumumab offers beneficial outcomes for relapsing multiple sclerosis by reducing relapse and disability progression risk. Additionally, Document [2] reports that ofatumumab demonstrated superior efficacy versus placebo in reducing gadolinium-enhancing T1 lesions and annualized T2 lesion and relapse rates. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]